The role of vitamin supplementation in the prevention of cardiovascular disease events

Clinical Cardiology

Volumn 37, Issue 9, 2014, Pages 576-581

  Desai, Chirag K ^a   Huang, Jennifer ^a   Lokhandwala, Adil ^a   Fernandez, Aaron ^a   Riaz, Irbaz Bin ^a   Alpert, Joseph S ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; HOMOCYSTEINE; MULTIVITAMIN; RETINOL; VITAMIN D; VITAMIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); HEART INFARCTION; HUMAN; VITAMIN SUPPLEMENTATION; AVITAMINOSIS; CARDIOVASCULAR DISEASES; DIET SUPPLEMENTATION; EVIDENCE BASED MEDICINE; RISK FACTOR; UNITED STATES;

AVITAMINOSIS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; HUMANS; RISK FACTORS; UNITED STATES; VITAMINS;

EID: 84905850687     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22299     Document Type: Article

References (54)

1. Sesso HD, Christen WG, Bubes V, et al. Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2012;308:1751-1760.
2. Hercberg S, Kesse-Guyot E, Druesne-Pecollo N, et al. Incidence of cancers, ischemic cardiovascular diseases and mortality during 5-year follow-up after stopping antioxidant vitamins and minerals supplements: a postintervention follow-up in the SU.VI.MAX Study. Int J Cancer. 2010;127:1875-1881.
3. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-128.
4. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359-364.
5. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202.
6. Abraham JM, Cho L. The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease? Cleve Clin J Med. 2010;77:911-918.
7. Armitage JM, Bowman L, Clarke RJ, et al. Effects of homocysteinelowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA. 2010;303:2486-2494.
8. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and totalmortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299:2027-2036.
9. VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the Vitamins to Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol. 2010;9:855-865.
10. Martí-Carvajal AJ, Solà I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2013;1:CD006612.
11. Weishaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. Am J Physiol. 1987;253(6 part 1):E675-E683.
12. Brondum-Jacobsen P, Benn M, Jensen GB, et al. 25-Hydroxyvitamin D levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Arterioscler Thromb Vasc Biol. 2012;32:2794-2802.
13. Tomson J, Emberson J, Hill M, et al. Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths. Eur Heart J. 2013;34:1365-1374.
14. Giovannucci E, Liu Y, Hollis BW, et al. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168:1174-1180.
15. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503-511.
16. Kendrick J, Targher G, Smits G, et al. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2009;205:255-260.
17. Kim DH, Sabour S, Sagar UN, et al. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol. 2008;102:1540-1544.
18. Andrukhova O, Slavic S, Zeitz U, et al. Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol Endocrinol. 2014;28:53-64.
19. Ish-Shalom M, Sack J, Vechoropoulos M, et al. Low-dose calcitriol decreases aortic renin, blood pressure, and atherosclerosis in apoE-null mice. J Atheroscler Thromb. 2012;19:422-434.
20. Tukaj S, Trzonkowski P, Tukaj C. Regulatory effects of 1,25-dihydroxyvitamin D3 on vascular smooth muscle cells. Acta Biochim Pol. 2012;59:395-400.
21. Takeda M, Yamashita T, Sasaki N, et al. Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler Thromb Vasc Biol. 2010;30:2495-2503.
22. Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D, Calcium. The National Academies Collection: Reports funded by National Institutes of Health. In: Ross AC, Taylor CL, Yaktine AL, et al, eds. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2011.
23. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline [published correction appears in J Clin Endocrinol Metab. 2011;96:3908]. J Clin Endocrinol Metab. 2011;96:1911-1930.
24. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation. 2007;115:846-854.
25. Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:1931-1942.
26. Manson JE, Bassuk SS, Lee IM, et al. The Vitamin D and Omega-3 Trial (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33: 159-171.
27. Liu S, Manson JE, Lee IM, et al. Fruit and vegetable intake and risk of cardiovascular disease: the Women's Health Study. Am J Clin Nutr. 2000;72:922-928.
28. Esterbauer H, Striegl G, Puhl H, et al. The role of vitamin E and carotenoids in preventing oxidation of low density lipoproteins. Ann N Y Acad Sci. 1989;570:254-267.
29. Higdon J, Linus Pauling Institute. Vitamin A. http://lpi.oregonstate.edu/infocenter/vitamins/vitaminA/. Published December 2003. Updated November 2007. Accessed April 24, 2014.
30. Mottaghi A, Salehi E, Keshvarz A, et al. The influence of vitamin A supplementation on Foxp3 and TGF-β gene expression in atherosclerotic patients. J Nutrigenet Nutrigenomics. 2012;5:314-326.
31. Harari A, Harats D, Marko D, et al. A 9-cis beta-carotene-enriched diet inhibits atherogenesis and fatty liver formation in LDLreceptor knockout mice. J Nutr. 2008;138:1923-1930.
32. Törnwall ME, Virtamo J, Korhonen PA, et al. Effect of alpha-tocopherol and beta-carotene supplementation on coronary heart disease during the 6-year post-trial follow-up in the ATBC study. Eur Heart J. 2004;25:1171-1178.
33. Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med. 2007;167:1610-1618.
34. Lee IM, Cook NR, Manson JE, et al.Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst. 1999;91:2102-2106.
35. Qiao H, Bell J, Juliao S, et al. Ascorbic acid uptake and regulation of type I collagen synthesis in cultured vascular smooth muscle cells. J Vasc Res. 2009;46:15-24.
36. May JM, Qu ZC. Ascorbic acid prevents increased endothelial permeability caused by oxidized low density lipoprotein. Free Radic Res. 2010;44:1359-1368.
37. Samsam Shariat SZ, Mostafavi SA, Khakpour F. Antioxidant effects of vitamins C and E on the low-density lipoprotein oxidation mediated by myeloperoxidase. Iran Biomed J. 2013;17:22-28.
38. Ye Z, Song H. Antioxidant vitamins intake and the risk of coronary heart disease: meta-analysis of cohort studies. Eur J Cardiovasc Prev Rehabil. 2008;15:26-34.
39. Myung SK, Ju W, Cho B, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;346:f10.
40. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2008;300:2123-2133.
41. Knekt P, Ritz J, Pereira MA, et al. Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts. Am J Clin Nutr. 2004;80:1508-1520.
42. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450-1456.
43. Wallert M, Mosig S, Rennert K, et al. Long-chain metabolites of alpha-tocopherol occur in human serum and inhibit macrophage foam cell formation in vitro. Free Radic Biol Med. 2014;68:43-51.
44. Qureshi AA, Karpen CW, Qureshi N, et al. Tocotrienols-induced inhibition of platelet thrombus formation and platelet aggregation in stenosed canine coronary arteries. Lipids Health Dis. 2011;10:58.
45. Niki E. Do free radicals play causal role in atherosclerosis? Low density lipoprotein oxidation and vitamin E revisited. J Clin Biochem Nutr. 2011;48:3-7.
46. National Institutes of Health, Office of Dietary Supplements. Vitamin E: fact sheet for health professionals. http://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional. Published June 2013. Accessed April 24, 2014.
47. Leppälä JM, Virtamo J, Fogelholm R, et al. Controlled trial of alphatocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol. 2000;20:230-235.
48. Vardi M, Blum S, Levy AP. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. Eur J Intern Med. 2012;23:628-632.
49. Milman U, Blum S, Shapira C, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol. 2008;28:341-347.
50. Yusuf S, Dagenais G, Pogue J, et al The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154-160.
51. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:56-65.
52. LamasGA, Boineau R, Goertz C, et al. Oral high-dosemultivitamins and minerals after myocardial infarction: a randomized trial. Ann Intern Med. 2013;159:797-805.
53. Rembold CM; ACP Journal Club. Review: vitamin and antioxidant supplements do not prevent adverse cardiovascular events. Ann Intern Med. 2013;158:JC10.
54. Fortmann SP, Burda BU, Senger CA, et al. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the US Preventive Services Task Force. Ann Intern Med. 2013;159:824-834.